Aptadir raises EUR 40 million seed round backed by Angelini Ventures

Aptadir Therapeutics raised EUR 40 million in a seed round to advance RNA inhibitor medicines targeting gene silencing, with Angelini Ventures participating and 4BIO Capital leading.